Viewing Study NCT00383760

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:16 AM
Ignite Modification Date: 2026-03-06 @ 10:57 AM
Study NCT ID: NCT00383760
Status: COMPLETED
Last Update Posted: 2017-10-20
First Post: 2006-09-29
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Adenocarcinoma of the Pancreas View
None Pancreatic Cancer View
None Recurrent Pancreatic Cancer View
None Stage II Pancreatic Cancer View
None Stage III Pancreatic Cancer View
None Stage IV Pancreatic Cancer View
Keywords: